ThermoGenesis, Biomet ink fibrin sealant deal
This article was originally published in Clinica
Executive Summary
Biomet is to access the $450m fibrin sealant market through a development, licence and supply agreement between its orthobiologics division and ThermoGenesis, the Rancho Cordova, California-based developer of automated blood processing systems.